Skip to main content

CG Oncology, Inc 10-Q for FY2026 Q3

CG Oncology, Inc. (CGON)

10-Q 2026-11-06 For: 2026-09-30
View Original
Added on November 06, 2026

About this 10-Q

CG Oncology, Inc filed this 10-Q on November 6, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

CG Oncology reported a $196.1 million net loss for the nine months ended September 30, 2026, up from $119.7 million, as R&D expenses increased to $137.6 million. Cash, cash equivalents and marketable securities totaled $984.5 million. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$1.6M
down 3.7% from $1.67M a year earlier
Net loss
$56.89M
compared with a net loss of $43.81M a year earlier
Diluted EPS
-$0.64
compared with -$0.57 a year earlier